文献速递临床免疫临床微生物分子诊断

扩大生物样本可及性以促进莱姆病检测开发

Expanding Access to Biospecimens for Lyme Disease Test Development.
PubMed 文献 · J Clin Microbiol · 2020-05-26

莱姆病实验室诊断依赖血清学两步法,但早期敏感性不足。Horn等建立了莱姆病生物样本库,从三个流行区纳入临床分类的早期莱姆病患者和健康对照,采集全血和尿液集中储存。直接检测阳性率低,标准两步法血清阳性率也较低,康复期血清转换者少。该队列含替代样本类型,为新型检测开发提供资源。

要点

  • 莱姆病血清学两步法在早期莱姆病中敏感性不足,需开发更敏感方法。
  • 生物样本库纳入临床分类的早期患者和健康对照,提供全血、血清和尿液。
  • 该队列直接检测阳性少,标准两步法血清阳性率低,血清转换者少。

核心结论

  • 该临床和血清学定义的莱姆病及对照样本队列,包含替代样本类型,为新型检测开发提供额外宝贵资源。

研究设计与样本

  • Horn等在《Journal of Clinical Microbiology》描述了莱姆病生物样本库的建立。
  • 从三个莱姆病流行区纳入临床分类的早期莱姆病患者和健康对照,未做实验室诊断检测。
  • 受试者提供全血和尿液,处理并储存于中央生物样本库,制备全血、血清和尿液分装供研究者使用。

主要发现

  • 获得样本后进行了广泛实验室检测,包括针对伯氏疏螺旋体和其他蜱传病原体的血清学和核酸扩增检测。
  • 直接检测方法阳性结果很少。
  • 与另一常用生物样本库队列相比,标准两步法检测显示血清阳性率低。
  • 康复期样本检测显示相对少数受试者出现血清转换。

临床怎么用

  • 该样本队列可用于开发莱姆病实验室诊断,包括替代样本类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The laboratory diagnosis of Lyme disease relies upon serologic testing. A standard or modified two-tiered testing algorithm is used to enhance the accuracy of antibody detection. However, this approach suffers from a lack of sensitivity in early Lyme disease. Ongoing efforts to develop more sensitive antibody detection technologies and other diagnostic approaches are dependent upon the availability of quality-assured biospecimens linked to reliable clinical data. In this issue of the Journal of Clinical Microbiology, Horn et al. (E. J. Horn, G. Dempsey, A. M. Schotthoefer, U. L. Prisco, et al., J Clin Microbiol 58:e00032-20, 2020, https://doi.org/10.1128/JCM.00032-20) described the development of the Lyme Disease Biobank. Clinically categorized case patients with early Lyme disease and healthy controls were identified (without laboratory diagnostic testing) from three sites where Lyme disease is endemic. Subjects provided whole blood and urine, which were processed and stored at a central biorepository. Whole blood, serum, and urine aliquots were prepared and are available to investigators developing laboratory diagnostics for Lyme disease. After obtaining samples, extensive laboratory testing was performed, including serologic and nucleic acid amplification testing for B. burgdorferi and other tick-borne pathogens. Direct detection methods yielded few positive results. Relative to the findings for another commonly used biorepository cohort, the results of this testing demonstrated a low seropositive rate, as determined by standard two-tiered testing. Additionally, relatively few subjects demonstrated seroconversion with testing of convalescent-phase samples. This clinical and serologically defined cohort of samples from Lyme disease and control cases from areas of Lyme disease endemicity offers an additional valuable resource for novel test development that includes alternate specimen types.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Schmitz JL. Expanding Access to Biospecimens for Lyme Disease Test Development. J Clin Microbiol. 2020. PMID: 32188688. doi:10.1128/JCM.00449-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。